{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:30:27Z","timestamp":1790566227095,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s11239-020-02151-2","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T06:03:32Z","timestamp":1590473012000},"page":"102-111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer"],"prefix":"10.1007","volume":"51","author":[{"given":"Hiroki","family":"Ueyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2487-8366","authenticated-orcid":false,"given":"Toshiki","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"issue":"1","key":"2151_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(01)00619-2","volume":"3","author":"GY Lip","year":"2002","unstructured":"Lip GY, Chin BS, Blann AD (2002) Cancer and the prothrombotic state. Lancet Oncol 3(1):27\u201334","journal-title":"Lancet Oncol"},{"issue":"3","key":"2151_CR2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632\u2013634","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2151_CR3","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","volume":"18","author":"BA Hutten","year":"2000","unstructured":"Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18(17):3078\u20133083","journal-title":"J Clin Oncol"},{"issue":"7","key":"2151_CR4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.9243","volume":"314","author":"AYY Lee","year":"2015","unstructured":"Lee AYY, Kamphuisen PW, Meyer G et al (2015) Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314(7):677\u2013686","journal-title":"JAMA"},{"issue":"2","key":"2151_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146\u2013153","journal-title":"N Engl J Med"},{"issue":"10","key":"2151_CR6","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","volume":"20","author":"D Farge","year":"2019","unstructured":"Farge D, Frere C, Connors JM et al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566\u2013e581","journal-title":"Lancet Oncol"},{"issue":"5","key":"2151_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496\u2013520","journal-title":"J Clin Oncol"},{"issue":"2","key":"2151_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane 2nd","year":"2020","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18(2):411\u2013421","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2151_CR9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615\u2013624","journal-title":"N Engl J Med"},{"issue":"20","key":"2151_CR10","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017\u20132023","journal-title":"J Clin Oncol"},{"key":"2151_CR11","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382:1599","journal-title":"N Engl J Med"},{"issue":"10","key":"2151_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1\u201334","journal-title":"J Clin Epidemiol"},{"key":"2151_CR13","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"issue":"12","key":"2151_CR14","doi-asserted-by":"publisher","first-page":"e115065","DOI":"10.1371\/journal.pone.0115065","volume":"9","author":"B Neupane","year":"2014","unstructured":"Neupane B, Richer D, Bonner AJ, Kibret T, Beyene J (2014) Network meta-analysis using R: a review of currently available automated packages. PLoS ONE 9(12):e115065","journal-title":"PLoS ONE"},{"issue":"7414","key":"2151_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"15","key":"2151_CR16","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","volume":"162","author":"G Meyer","year":"2002","unstructured":"Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162(15):1729\u20131735","journal-title":"Arch Intern Med"},{"issue":"6","key":"2151_CR17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ejvs.2004.02.029","volume":"29","author":"ME Daskalopoulos","year":"2005","unstructured":"Daskalopoulos ME, Daskalopoulou SS, Tzortzis E et al (2005) Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 29(6):638\u2013650","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"2","key":"2151_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0741-5214(99)70139-4","volume":"30","author":"JA Gonzalez-Fajardo","year":"1999","unstructured":"Gonzalez-Fajardo JA, Arreba E, Castrodeza J et al (1999) Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 30(2):283\u2013292","journal-title":"J Vasc Surg"},{"issue":"12","key":"2151_CR19","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","volume":"119","author":"RD Hull","year":"2006","unstructured":"Hull RD, Pineo GF, Brant RF et al (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119(12):1062\u20131072","journal-title":"Am J Med"},{"issue":"1","key":"2151_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1067\/mva.2001.109336","volume":"33","author":"P Lopez-Beret","year":"2001","unstructured":"Lopez-Beret P, Orgaz A, Fontcuberta J et al (2001) Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 33(1):77\u201390","journal-title":"J Vasc Surg"},{"issue":"4","key":"2151_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/1076029606293692","volume":"12","author":"SR Deitcher","year":"2006","unstructured":"Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12(4):389\u2013396","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"2151_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ejvs.2008.11.030","volume":"37","author":"A Romera","year":"2009","unstructured":"Romera A, Cairols MA, Vila-Coll R et al (2009) A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 37(3):349\u2013356","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"4","key":"2151_CR23","first-page":"559","volume":"84","author":"F Veiga","year":"2000","unstructured":"Veiga F, Escriba A, Maluenda MP et al (2000) Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 84(4):559\u2013564","journal-title":"Thromb Haemost"},{"issue":"12","key":"2151_CR24","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/jth.13153","volume":"13","author":"G Agnelli","year":"2015","unstructured":"Agnelli G, Buller HR, Cohen A et al (2015) Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 13(12):2187\u20132191","journal-title":"J Thromb Haemost"},{"issue":"26","key":"2151_CR25","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499\u20132510","journal-title":"N Engl J Med"},{"issue":"14","key":"2151_CR26","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR Buller","year":"2012","unstructured":"Buller HR, Prins MH, Lensin AW et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287\u20131297","journal-title":"N Engl J Med"},{"issue":"8","key":"2151_CR27","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","volume":"3","author":"GE Raskob","year":"2016","unstructured":"Raskob GE, van Es N, Segers A et al (2016) Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 3(8):e379\u2013387","journal-title":"Lancet Haematol"},{"issue":"24","key":"2151_CR28","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342\u20132352","journal-title":"N Engl J Med"},{"issue":"7","key":"2151_CR29","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ et al (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129(7):764\u2013772","journal-title":"Circulation"},{"issue":"1","key":"2151_CR30","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2352-3026(18)30191-1","volume":"6","author":"GK Dawwas","year":"2019","unstructured":"Dawwas GK, Brown J, Dietrich E, Park H (2019) Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol 6(1):e20\u2013e28","journal-title":"Lancet Haematol"},{"issue":"12","key":"2151_CR31","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1016\/j.mayocp.2019.05.035","volume":"94","author":"HE Fuentes","year":"2019","unstructured":"Fuentes HE, McBane RD II, Wysokinski WE et al (2019) Direct oral factor Xa inhibitors for the treatment of acute cancer-associated venous thromboembolism: a systematic review and network meta-analysis. Mayo Clin Proc 94(12):2444\u20132454","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2151_CR32","doi-asserted-by":"publisher","first-page":"e99276","DOI":"10.1371\/journal.pone.0099276","volume":"9","author":"A Clemens","year":"2014","unstructured":"Clemens A, Noack H, Brueckmann M, Lip GY (2014) Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria. PLoS ONE 9(6):e99276","journal-title":"PLoS ONE"},{"issue":"2","key":"2151_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1185\/03007995.2011.654109","volume":"28","author":"A Clemens","year":"2012","unstructured":"Clemens A, Haertter S, Friedman J et al (2012) Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin 28(2):195\u2013201","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2151_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","volume":"53","author":"W Mueck","year":"2014","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M (2014) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 53(1):1\u201316","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2151_CR35","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/bcp.12106","volume":"76","author":"C Frost","year":"2013","unstructured":"Frost C, Nepal S, Wang J et al (2013) Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 76(5):776\u2013786","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"2151_CR36","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0091270009351883","volume":"50","author":"K Ogata","year":"2010","unstructured":"Ogata K, Mendell-Harary J, Tachibana M et al (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50(7):743\u2013753","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"2151_CR37","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","volume":"1","author":"MH Prins","year":"2014","unstructured":"Prins MH, Lensing AW, Brighton TA et al (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 1(1):e37\u201346","journal-title":"Lancet Haematol"},{"issue":"1","key":"2151_CR38","first-page":"150","volume":"114","author":"S Schulman","year":"2015","unstructured":"Schulman S, Goldhaber SZ, Kearon C et al (2015) Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 114(1):150\u2013157","journal-title":"Thromb Haemost"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-020-02151-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-020-02151-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-020-02151-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T23:21:41Z","timestamp":1621984901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-020-02151-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1007\/s11239-020-02151-2","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"26 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}